CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $230.68M, above the global median of $16.24M
- PositionCurrent ratio is 0.24×, lower than 95% of its Biotechnology peers (median 5.64×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.58BCNY680.62M · vs all stocks (USD)
Revenue (TTM)
1.53BCNY227.02M · vs all stocks (USD)
Profit Margin
-92.63%vs Biotechnology peers
Beta
0.5620xvs all stocks
52-Week Change
-37.40%vs all stocks
Market Capitalization
4.58BCNY680.62M · vs all stocks (USD)
Enterprise Value
6.39BCNY949.51M · vs all stocks (USD)
Forward P/E
24.52xvs Biotechnology peers
Price to Sales (TTM)
3.08xvs Biotechnology peers
Enterprise to Revenue
4.18xvs Biotechnology peers
Enterprise to EBITDA
57.71xvs Biotechnology peers
Gross Margin
35.48%vs Biotechnology peers
Profit Margin
-92.63%vs Biotechnology peers
Operating Margin
7.86%vs Biotechnology peers
Return on Assets (TTM)
-0.63%vs Biotechnology peers
Revenue (TTM)
1.53BCNY227.02M · vs all stocks (USD)
Revenue per Share (TTM)
2.33CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-15.90%vs Biotechnology peers
Gross Profit (TTM)
425.11MCNY63.14M · vs all stocks (USD)
EBITDA (TTM)
110.78MCNY16.45M · vs all stocks (USD)
Net Income (TTM)
-1.42BCNY-210.29M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.94%vs Biotechnology peers
Operating Cash Flow (TTM)
156.09MCNY23.18M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.55BCNY230.68M · vs all stocks (USD)
5-Year Average Dividend Yield
0.82%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
404.27MCNYFY2025 · Dec 31, 2025Revenue
1.60BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.16BCNYFY2025 · Dec 31, 2025Gross Profit
435.94MCNYFY2025 · Dec 31, 2025Operating Income
-76.60MCNY-11.38M · vs all stocks (USD)
Pre-tax Income
-1.34BCNYFY2025 · Dec 31, 2025Income Tax Expense
33.95MCNYFY2025 · Dec 31, 2025Net Income
-1.37BCNYFY2025 · Dec 31, 2025EBIT
-1.05BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-289.75MCNYFY2025 · Dec 31, 2025Research & Development
70.95MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
155.27MCNYFY2025 · Dec 31, 2025Other Operating Expenses
27.11MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
794.99KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
284.06MCNYFY2025 · Dec 31, 2025EPS (Basic)
-2.11CNYFY2025 · Dec 31, 2025EPS (Diluted)
-2.11CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
659.80MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
659.80MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-1.37BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-21.39MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-998.04MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.01BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
245.66MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.37BCNYFY2025 · Dec 31, 2025Other Non-cash Items
290.96MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
40.61MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
41.18MCNYFY2025 · Dec 31, 2025Capital Expenditures
-16.50MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-1.64MCNYFY2025 · Dec 31, 2025Sale of Investments
5.60MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-12.54MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
59.60MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-65.93MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-5.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
10.67MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.50MCNYFY2025 · Dec 31, 2025Shares Outstanding
661.28MSharesUpdated Aug 19, 2026Float Shares
478.94MSharesUpdated Aug 19, 2026% Held by Insiders
34.56%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
144.74MCNY21.50M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2210CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.44BCNY213.45M · vs all stocks (USD)
Current Ratio (MRQ)
0.2390xvs Biotechnology peers
Book Value per Share (MRQ)
-0.7190CNYUpdated Aug 19, 2026Total Assets
6.75BCNY1.00B · vs all stocks (USD)
Total Current Assets
1.61BCNYFY2025 · Dec 31, 2025Total Liabilities
6.70BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.14BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
530.23MCNYFY2025 · Dec 31, 2025Total Current Liabilities
6.17BCNYFY2025 · Dec 31, 2025Cash
254.52MCNYFY2025 · Dec 31, 2025Cash Equivalents
51.30KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
254.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
750.42MCNYFY2025 · Dec 31, 2025Inventory
295.43MCNYFY2025 · Dec 31, 2025Accounts Payable
1.19BCNYFY2025 · Dec 31, 2025Short-term Debt
1.00BCNYFY2025 · Dec 31, 2025Other Current Liabilities
43.29MCNYFY2025 · Dec 31, 2025Long-term Debt
464.57MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.61MCNYFY2025 · Dec 31, 2025Common Stock (Book)
661.28MCNYFY2025 · Dec 31, 2025Retained Earnings
-3.23BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
43.95MCNY6.53M · vs all stocks (USD)
Treasury Stock
8.50MCNYFY2025 · Dec 31, 202552-Week Low
5.90CNYUpdated Aug 19, 202652-Week High
12.79CNYUpdated Aug 19, 202652-Week Change
-37.40%vs all stocks
Beta
0.5620xvs all stocks
50-Day MA
8.13CNYUpdated Aug 19, 2026200-Day MA
9.28CNYUpdated Aug 19, 2026Avg 10-Day Volume
9.83MSharesUpdated Aug 19, 2026Avg 30-Day Volume
12.74MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-2.15CNYUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.24×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.24Industry median: 5.64Industry P5: 1.06Peers compared: 261
Financial Health
Altman Z-Score -1.35: distress zoneCritical
Altman Z-Score: -1.35
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $230.68M, above the global median of $16.24MNotable
Levered free cash flow (USD): 230,683,716.362Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Supriya Lifescience Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Eagle High Plantations Tbk
3 interpretationsElevated Leverage on Three DenominatorsPartial Recovery After Sharp DeclineWithin or Near the Altman Distress Zone
Sigma Lithium Corporation
3 interpretationsElevated Leverage on Three DenominatorsPartial Recovery After Sharp DeclineWithin or Near the Altman Distress Zone
Hunan Huamin Holdings Co., Ltd.
3 interpretationsElevated Leverage on Three DenominatorsPartial Recovery After Sharp DeclineWithin or Near the Altman Distress Zone